Christoffer V. Heidtmann, Christian Ding Fisker, Sarah Løgstrup, Patrick G. Eriksen, Louise H. Storm, Kristian Stærk, Laust Moesgaard, Maria Pedersen, Martin J. Madsen, Ahmed Yusuf, Krista Urup, Iben S. Højgaard, Jayappragash Ramesh, Rasmus H. Pihlsbech, Caroline B. Sørensen, Tore L. Rønn, Alexander B. Larsen, Laurits R. Caspersen, Mathias Æ. Møller, Chris R. Sixhøj, Niels Frimodt-Møller, Janne K. Klitgaard, Thomas E. Andersen, Carsten U. Nielsen, Poul Nielsen
{"title":"Linker and Head-Group Exploration of Anti-MRSA Triaromatic Pleuromutilins","authors":"Christoffer V. Heidtmann, Christian Ding Fisker, Sarah Løgstrup, Patrick G. Eriksen, Louise H. Storm, Kristian Stærk, Laust Moesgaard, Maria Pedersen, Martin J. Madsen, Ahmed Yusuf, Krista Urup, Iben S. Højgaard, Jayappragash Ramesh, Rasmus H. Pihlsbech, Caroline B. Sørensen, Tore L. Rønn, Alexander B. Larsen, Laurits R. Caspersen, Mathias Æ. Møller, Chris R. Sixhøj, Niels Frimodt-Møller, Janne K. Klitgaard, Thomas E. Andersen, Carsten U. Nielsen, Poul Nielsen","doi":"10.1021/acs.jmedchem.5c00152","DOIUrl":null,"url":null,"abstract":"Based on hit <b>6</b>, a triaromatic pleuromutilin (TAP) and potent bacterial protein synthesis inhibitor, we explored the chemical space surrounding its pharmacophore by synthesizing 45 new conjugates. Herein, the adenine head was exchanged for new heterocycles, and the benzyl linker exchanged for aniline-, ether-, amide-, and hydroxybenzyl linkages, with all of them successfully engaging the pharmacophore, a result which was mirrored in a strict 3D pharmacophore model. The aniline- and amide-linked conjugates moreover demonstrated greater stability in liver microsomes, while especially conjugate <b>21</b>, but also <b>31</b>, <b>43</b>, <b>45</b>, and <b>55</b> displayed excellent potency, with MRSA activities on par with <b>6</b> or better. Docking to the ribosome suggested a shifted engagement with C2469 for <b>21</b> over <b>6</b>, resulting in greater multivalency, while <b>43</b>/<b>45</b> likely coordinates Mg<sup>2+</sup>. Lastly, conjugate <b>21</b> displayed efficacy equal to commercial Fucidin LEO (<b>5</b>) in a mouse <i>Staphylococcus aureus</i> skin infection model, highlighting its potential as a topical antibiotic lead.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"3 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00152","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Based on hit 6, a triaromatic pleuromutilin (TAP) and potent bacterial protein synthesis inhibitor, we explored the chemical space surrounding its pharmacophore by synthesizing 45 new conjugates. Herein, the adenine head was exchanged for new heterocycles, and the benzyl linker exchanged for aniline-, ether-, amide-, and hydroxybenzyl linkages, with all of them successfully engaging the pharmacophore, a result which was mirrored in a strict 3D pharmacophore model. The aniline- and amide-linked conjugates moreover demonstrated greater stability in liver microsomes, while especially conjugate 21, but also 31, 43, 45, and 55 displayed excellent potency, with MRSA activities on par with 6 or better. Docking to the ribosome suggested a shifted engagement with C2469 for 21 over 6, resulting in greater multivalency, while 43/45 likely coordinates Mg2+. Lastly, conjugate 21 displayed efficacy equal to commercial Fucidin LEO (5) in a mouse Staphylococcus aureus skin infection model, highlighting its potential as a topical antibiotic lead.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.